Two phase 3 studies show that Eli Lilly and Company's (NYSE: LLY) ultra rapid lispro (URLi) provided non-inferior A1C reductions compared to Humalog® (insulin lispro) at 26 weeks in people with...

SC Johnson and the United Nations Association of the United States of America (UNA-USA) will host a screening today of the acclaimed film "Love Sonia," the story of a young girl's journey to...

In a comparison of two different diet and two different weight management programs, results of the international PREVIEW intervention study found a low, similar rate of progression to type 2...

Results from several studies of Eli Lilly and Company's (NYSE: LLY) investigational dual GIP and GLP-1 receptor agonist (RA), tirzepatide, reinforce its potential in lowering A1C and body weight...

Brad Keywell, CEO of US-based Uptake Technologies, Inc., was this evening named EY World Entrepreneur Of The Year™ 2019 at an award ceremony held in Monaco's Salle des Etoiles. Brad was selected...

By continuing to follow the cohort from the Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Study sponsored by the National Institutes of Health (NIH), researchers can now...

The iLet bionic pancreas (BP)1 significantly increased the percentage of time adults with type 1 diabetes (T1D) had glucose levels between 70–180 mg/dl, when compared to usual care (UC) therapy...

Pancreatic beta cells that do not produce sufficient insulin in people with type 2 diabetes (T2D) are not permanently damaged during the early stages of the disease and can be restored to normal...

Continuous glucose monitoring (CGM) evaluations in islet transplant recipients who have been insulin independent for an average of 10 years show near-normal glycemic profiles and time-in-range...

One Drop, a leader in the development of digital therapeutics solutions for diabetes and other chronic conditions, today announced the expansion of their AI-powered Predictive Insights to include...